Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of eight systematic review(s)/meta-analysis(es). ^[1-2]
• Predictive Value for Progression-Free Survival (PFS): In patients with neuroendocrine neoplasms (NENs), 64Cu-DOTATATE uptake measured by maximum standardized uptake value (SUVmax) was prognostic for PFS, with an SUVmax cutoff of 43.3 associated with a Hazard Ratio (HR) of 0.56 (95% confidence interval (CI): 0.38–0.84). The accuracy for predicting PFS at 24 months was moderate at 57%.
• Diagnostic Performance: In patients with somatostatin receptor (SSTR)-expressing neuroendocrine tumors (NETs), 64Cu-DOTATATE Positron Emission Tomography/Computed Tomography (PET/CT) demonstrated high sensitivity (90.9%) and specificity (96.6%), which increased to 100.0% and 96.8%, respectively, after correcting for an initial standard-of-truth misread. The method reliably distinguished between localized and metastatic disease.
• No adverse events were related to the administration of 64Cu-DOTATATE, and no serious adverse events were observed during the study period (injection through 48 hours post-injection).
• No significant safety concerns or adverse effects were reported in the reviewed studies.
• The reviewed studies focused on patients with NENs and SSTR-expressing NETs, highlighting the prognostic value of 64Cu-DOTATATE uptake for PFS in NENs without demonstrating Overall Survival (OS) benefits, and its high diagnostic sensitivity and specificity for SSTR-expressing NETs, with no significant subgroup differences noted.